2009-2018 年美国丁丙诺啡治疗趋势。
Trends in Buprenorphine Treatment in the United States, 2009-2018.
机构信息
Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
School of Management, Yale University, New Haven, Connecticut.
出版信息
JAMA. 2020 Jan 21;323(3):276-277. doi: 10.1001/jama.2019.18913.
Abstract
This study assessed the number of individuals receiving treatment for opioid use disorder in the United States by age group and sex using a national prescription database to compare between the number of buprenorphine prescriptions filled and the number of US opioid-related overdose deaths.
摘要
本研究使用全国处方数据库评估了美国按年龄组和性别划分的接受阿片类药物使用障碍治疗的人数，以比较丁丙诺啡处方的数量和美国阿片类药物相关过量死亡人数。
相似文献
1
Trends in Buprenorphine Treatment in the United States, 2009-2018.2009-2018 年美国丁丙诺啡治疗趋势。
JAMA. 2020 Jan 21;323(3):276-277. doi: 10.1001/jama.2019.18913.
2
Trends and Disparities in Initiation of Buprenorphine in US Emergency Departments, 2013-2022.2013 - 2022年美国急诊科丁丙诺啡起始治疗的趋势与差异
JAMA Netw Open. 2024 Sep 3;7(9):e2435603. doi: 10.1001/jamanetworkopen.2024.35603.
3
Buprenorphine Dispensing after Elimination of the Waiver Requirement.豁免要求取消后的丁丙诺啡配药
N Engl J Med. 2024 Apr 25;390(16):1530-1532. doi: 10.1056/NEJMc2312906.
4
US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.2011 - 2016年期间，美国急诊科与阿片类药物相关的就诊人数增加，而用于阿片类药物使用障碍的药物使用情况难以察觉。
J Gen Intern Med. 2020 Mar;35(3):965-966. doi: 10.1007/s11606-019-05249-3.
5
National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019-2021.2019 - 2021年美国国家级和州级基于药房的丁丙诺啡配药情况
J Gen Intern Med. 2024 Aug;39(10):1951-1953. doi: 10.1007/s11606-024-08829-0. Epub 2024 May 28.
6
The Number Needed to Prescribe - What Would It Take to Expand Access to Buprenorphine?处方所需数量——扩大丁丙诺啡可及性需要什么？
N Engl J Med. 2021 May 13;384(19):1783-1784. doi: 10.1056/NEJMp2101298. Epub 2021 May 8.
7
Why 24 State and Territorial Health Officials Support Buprenorphine Deregulation.为何24位州和领地卫生官员支持丁丙诺啡管制放松。
Am J Public Health. 2019 Dec;109(12):1678-1679. doi: 10.2105/AJPH.2019.305370.
8
Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.美国食品药品监督管理局批准缓释丁丙诺啡用于治疗阿片类药物依赖：发挥其潜力。
Addiction. 2017 Mar;112(3):386-387. doi: 10.1111/add.13539. Epub 2016 Aug 26.
9
Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.2007 - 2017年美国丁丙诺啡豁免处方医生的增长与分布情况
Ann Intern Med. 2020 Apr 7;172(7):504-506. doi: 10.7326/M19-2403. Epub 2020 Jan 7.
10
A New Way Forward in the Emergency Department.急诊科的新发展方向。
J Med Toxicol. 2019 Oct;15(4):220-222. doi: 10.1007/s13181-019-00718-x. Epub 2019 Jul 5.
引用本文的文献
1
"All I want is the best for my brother": interest in a Community Reinforcement and Family Training (CRAFT)-based group intervention among concerned significant others of individuals on office-based medications for opioid use disorder.“我只希望我哥哥能得到最好的”：对基于社区强化和家庭训练（CRAFT）的团体干预的兴趣，该干预针对使用办公室药物治疗阿片类物质使用障碍的个人的相关重要他人。
BMC Psychiatry. 2025 Jul 31;25(1):748. doi: 10.1186/s12888-025-07132-4.
2
Suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone.使用丁丙诺啡-纳洛酮与长效纳曲酮治疗的阿片类物质使用障碍成年患者的自杀意念
Am J Drug Alcohol Abuse. 2025 Jul 11:1-9. doi: 10.1080/00952990.2025.2524110.
3
The 2016 CDC Opioid Guideline and Analgesic Prescribing Patterns in Older Adults With Cancer.2016年美国疾病控制与预防中心阿片类药物指南及老年癌症患者的镇痛处方模式
JAMA Netw Open. 2025 May 1;8(5):e259043. doi: 10.1001/jamanetworkopen.2025.9043.
4
Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response.丁丙诺啡治疗反应的多祖先全基因组关联荟萃分析。
Neuropsychopharmacology. 2025 May 6. doi: 10.1038/s41386-025-02117-z.
5
From glitter to gold: recommendations for effective dashboards from design through sustainment.从华而不实到卓有成效：关于有效仪表盘从设计到维护的建议。
Implement Sci. 2025 Apr 22;20(1):16. doi: 10.1186/s13012-025-01430-x.
6
A randomized pilot trial of two forms of behavioral economics intervention to improve engagement in buprenorphine-naloxone treatment among patients with opioid use disorder.一项随机试点试验，比较两种行为经济学干预形式对改善阿片类药物使用障碍患者丁丙诺啡 - 纳洛酮治疗参与度的效果。
Drug Alcohol Depend. 2025 Mar 1;268:112584. doi: 10.1016/j.drugalcdep.2025.112584. Epub 2025 Jan 29.
7
The impact of buprenorphine prescriber data on geospatial access to treatment in HEALing Communities Study communities, 2022.丁丙诺啡处方医生数据对2022年HEALing Communities Study社区治疗地理空间可及性的影响
J Subst Use Addict Treat. 2025 Apr;171:209625. doi: 10.1016/j.josat.2025.209625. Epub 2025 Jan 27.
8
Art therapy's engagement of brain networks for enduring recovery from addiction.艺术疗法对大脑网络的参与作用，以实现成瘾的持久康复。
Front Psychiatry. 2025 Jan 6;15:1458063. doi: 10.3389/fpsyt.2024.1458063. eCollection 2024.
9
Trends in Opioid Use Disorder in the Veterans Health Administration, 2005-2022.2005 - 2022年退伍军人健康管理局阿片类药物使用障碍趋势
JAMA Netw Open. 2024 Dec 2;7(12):e2451821. doi: 10.1001/jamanetworkopen.2024.51821.
10
Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder.丁丙诺啡治疗时长的替代操作方式对理解阿片类物质使用障碍连续照护的影响
Int J Ment Health Addict. 2024 Aug;22(4):2285-2290. doi: 10.1007/s11469-022-00985-w.
本文引用的文献
1
US National Trends in Pediatric Deaths From Prescription and Illicit Opioids, 1999-2016.美国 1999-2016 年儿童因处方和非法阿片类药物死亡的国家趋势。
JAMA Netw Open. 2018 Dec 7;1(8):e186558. doi: 10.1001/jamanetworkopen.2018.6558.
2
Trends In Buprenorphine Prescribing By Physician Specialty.医生专业的丁丙诺啡处方趋势。
Health Aff (Millwood). 2019 Jan;38(1):24-28. doi: 10.1377/hlthaff.2018.05145.
3
Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.美沙酮使用与阿片类药物使用障碍治疗费用：2003 年至 2015 年趋势
Psychiatr Serv. 2018 Jul 1;69(7):832-835. doi: 10.1176/appi.ps.201700315. Epub 2018 May 8.
4
Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States.美国的非医疗处方阿片类药物使用及《精神疾病诊断与统计手册》第五版中的非医疗处方阿片类药物使用障碍
J Clin Psychiatry. 2016 Jun;77(6):772-80. doi: 10.4088/JCP.15m10386.
Zotero 插件